181 results Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe represents Helpling Stibbe represents Helpling in a case brought by the FNV. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe advises Synopsys Stibbe advises Synopsys, Inc., a Nasdaq listed technology company, in its acquisition of certain assets of Forcheck b.v. Stibbe advises Expedia on the IPO of trivago Expedia is one of the world’s leading travel companies, with an extensive brand portfolio that includes some of the world’s most trusted online travel brands, including trivago. Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Aan de slag met de nieuwe Wet hergebruik van overheidsinformatie Op 18 juli 2015 is de Wet hergebruik van overheidsinformatie (de "Who") in werking getreden. Burgers en bedrijven kunnen bij publieketaakinstellingen een verzoek indienen tot het verstrekken van overheidsinformatie. Minke Reijneveld Junior Associate Amsterdam Clémence Jonckheere Junior Associate Brussels Pagination Previous page Page 8 Page 9 Current page 10 Page 11 Next page
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe advises Synopsys Stibbe advises Synopsys, Inc., a Nasdaq listed technology company, in its acquisition of certain assets of Forcheck b.v.
Stibbe advises Expedia on the IPO of trivago Expedia is one of the world’s leading travel companies, with an extensive brand portfolio that includes some of the world’s most trusted online travel brands, including trivago.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Aan de slag met de nieuwe Wet hergebruik van overheidsinformatie Op 18 juli 2015 is de Wet hergebruik van overheidsinformatie (de "Who") in werking getreden. Burgers en bedrijven kunnen bij publieketaakinstellingen een verzoek indienen tot het verstrekken van overheidsinformatie.